Published in Ann Neurol on February 01, 2005
Plasma urate and risk of Parkinson's disease. Am J Epidemiol (2007) 3.06
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (2009) 2.49
Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci (2011) 2.40
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol (2008) 1.59
P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med (2008) 1.53
Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem (2008) 1.43
CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol (2009) 1.43
Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology (2015) 1.43
TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis (2007) 1.35
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm (Vienna) (2008) 1.25
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2007) 1.25
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation (2008) 1.22
Glutathione metabolism and Parkinson's disease. Free Radic Biol Med (2013) 1.20
Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol (2009) 1.20
Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One (2013) 1.14
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med (2010) 1.13
Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm (2013) 1.12
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
The blood-brain barrier: an engineering perspective. Front Neuroeng (2013) 1.09
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation (2012) 1.08
Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther (2010) 1.08
Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front Cell Neurosci (2014) 1.07
Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro (2013) 1.05
Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem (2008) 1.04
Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila. Glia (2011) 1.03
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell Mol Life Sci (2013) 1.02
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain (2011) 1.01
Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis (2010) 1.01
Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. Proc Natl Acad Sci U S A (2012) 1.01
Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol (2012) 1.00
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One (2012) 0.99
Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener (2015) 0.98
Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev (2009) 0.97
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol (2015) 0.97
Parkinson's disease and systemic inflammation. Parkinsons Dis (2011) 0.96
PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab (2011) 0.95
Neuroimaging in Parkinson's disease. Neurotherapeutics (2011) 0.95
Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94
(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. Nucl Med Biol (2013) 0.93
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. Neurobiol Dis (2009) 0.92
Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. Cell Mol Neurobiol (2009) 0.92
Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease. Front Neurosci (2016) 0.91
MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators Inflamm (2013) 0.91
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. Neuroimage (2012) 0.91
Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis (2011) 0.91
Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration. Mol Neurobiol (2013) 0.91
Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord (2011) 0.90
Human brain endothelial cells are responsive to adenosine receptor activation. Purinergic Signal (2011) 0.90
Formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration? Environ Health Perspect (2008) 0.90
Tissue-engineered microenvironment systems for modeling human vasculature. Exp Biol Med (Maywood) (2014) 0.89
(R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. BMC Med Imaging (2011) 0.89
The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis (2011) 0.89
Parkinson's disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation (2012) 0.88
Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol (2009) 0.88
Mesenchymal stem cells stabilize the blood-brain barrier through regulation of astrocytes. Stem Cell Res Ther (2015) 0.88
Transport rankings of non-steroidal antiinflammatory drugs across blood-brain barrier in vitro models. PLoS One (2014) 0.88
Profound olfactory dysfunction in myasthenia gravis. PLoS One (2012) 0.87
Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease. PLoS One (2015) 0.86
Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. Biomed Res Int (2014) 0.86
Eryptosis as a marker of Parkinson's disease. Aging (Albany NY) (2014) 0.86
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res (2015) 0.85
Peripheral inflammation in neurodegeneration. J Mol Med (Berl) (2013) 0.85
Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation (2011) 0.85
Cell-culture models of the blood-brain barrier. Stroke (2014) 0.85
MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol (2009) 0.85
Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab (2015) 0.84
Immune responses at brain barriers and implications for brain development and neurological function in later life. Front Integr Neurosci (2013) 0.84
Polarity proteins as regulators of cell junction complexes: implications for breast cancer. Pharmacol Ther (2013) 0.84
Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother (2015) 0.84
Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol (2007) 0.83
Current understanding of the glial response to disorders of the aging CNS. Front Pharmacol (2012) 0.82
Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides (2014) 0.81
Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice. Mol Neurobiol (2015) 0.81
Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects. Stem Cells Transl Med (2015) 0.80
Neurovascular unit in chronic pain. Mediators Inflamm (2013) 0.80
Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. J Pharmacol Exp Ther (2013) 0.80
Targeting specific cells in the brain with nanomedicines for CNS therapies. J Control Release (2015) 0.79
Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J Neural Transm (Vienna) (2009) 0.79
Dysregulation of Endoplasmic Reticulum Stress and Autophagic Responses by the Antiretroviral Drug Efavirenz. Mol Pharmacol (2015) 0.78
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing. Behav Brain Res (2007) 0.78
Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's disease. PLoS One (2014) 0.78
Opposite effects of bone marrow-derived cells transplantation in MPTP-rat model of Parkinson's disease: a comparison study of mononuclear and mesenchymal stem cells. Int J Med Sci (2014) 0.77
Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. J Neuroinflammation (2016) 0.77
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord (2012) 0.77
Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease. J Neurol (2016) 0.76
Automated Protein Localization of Blood Brain Barrier Vasculature in Brightfield IHC Images. PLoS One (2016) 0.76
Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease. Neural Regen Res (2015) 0.76
An in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats. Biomed Res Int (2014) 0.76
Glial regulation of the blood-brain barrier in health and disease. Semin Immunopathol (2015) 0.75
Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis. Medicine (Baltimore) (2016) 0.75
BBBomics-Human Blood Brain Barrier Transcriptomics Hub. Front Neurosci (2016) 0.75
CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease. Exp Mol Med (2016) 0.75
Hot spots: can positron emission tomography offer insights into the pathogenesis of PD? Ann Neurol (2005) 0.75
Transporters as Drug Targets in Neurological Diseases. Clin Pharmacol Ther (2016) 0.75
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell (2012) 2.76
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med (2004) 2.22
Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med (2009) 2.17
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol (2009) 2.02
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Handedness correlates with the dominant Parkinson side: a systematic review and meta-analysis. Mov Disord (2011) 1.84
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol (2010) 1.63
Approach and management of primary ectopic breast carcinoma in the axilla: where are we? A comprehensive historical literature review. J Plast Reconstr Aesthet Surg (2010) 1.40
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood (2006) 1.39
Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging (2002) 1.36
Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med (2003) 1.32
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging (2008) 1.30
Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28
Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord (2010) 1.22
Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer (2012) 1.18
Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain (2009) 1.15
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage (2003) 1.13
PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des (2004) 1.12
Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med (2010) 1.11
Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther (2002) 1.11
The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) (2011) 1.10
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord (2006) 1.09
In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med (2007) 1.09
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2012) 1.07
Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res (2012) 1.06
Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord (2013) 1.06
Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord (2007) 1.05
Brain imaging in patients with freezing of gait. Mov Disord (2008) 1.04
89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med (2013) 1.03
Enhancing surgical vision by using real-time imaging of αvβ3-integrin targeted near-infrared fluorescent agent. Ann Surg Oncol (2011) 1.03
Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med (2003) 1.02
Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging (2002) 1.02
PET for the evaluation of pleural thickening observed on CT. J Nucl Med (2004) 0.99
Late-onset Huntington disease with intermediate CAG repeats: true or false? J Neurol Neurosurg Psychiatry (2010) 0.99
Simultaneous EMG-functional MRI recordings can directly relate hyperkinetic movements to brain activity. Hum Brain Mapp (2008) 0.99
Striatal dopa and glucose metabolism in PD patients with freezing of gait. Mov Disord (2006) 0.99
Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Cortex (2008) 0.98
Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol (2009) 0.98
18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med (2004) 0.97
Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol (2005) 0.96
Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest (2013) 0.95
Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography. Clin Cancer Res (2013) 0.95
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer (2012) 0.94
Fact or factitious? A psychobiological study of authentic and simulated dissociative identity states. PLoS One (2012) 0.94
The impact of executive functions on verb production in patients with Parkinson's disease. Cortex (2009) 0.93
Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int J Neuropsychopharmacol (2009) 0.93
Cerebral activation during motor imagery in complex regional pain syndrome type 1 with dystonia. Pain (2007) 0.92
Psychobiological characteristics of dissociative identity disorder: a symptom provocation study. Biol Psychiatry (2006) 0.92
Changed patterns of cerebral activation related to clinically normal hand movement in cervical dystonia. Clin Neurol Neurosurg (2007) 0.92
Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging (2010) 0.92
PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med (2013) 0.91
Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med (2004) 0.91
Functional sex differences in human primary auditory cortex. Eur J Nucl Med Mol Imaging (2007) 0.91
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol (Dordr) (2011) 0.90
PET imaging of beta-adrenoceptors in human brain: a realistic goal or a mirage? Curr Pharm Des (2004) 0.90
18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. Nucl Med Commun (2006) 0.90
Measuring drug-related receptor occupancy with positron emission tomography. Methods (2002) 0.90
Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology (2010) 0.89
Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat Disord (2008) 0.89
Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cell Oncol (Dordr) (2014) 0.89
5-HT(1A) receptor imaging in the human brain: effect of tryptophan depletion and infusion on [(18)F]MPPF binding. Synapse (2002) 0.89
Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration. Curr Neuropharmacol (2010) 0.88
Cerebral activation patterns related to initiation and inhibition of hand movement. Neuroreport (2007) 0.88
Language and Parkinson's disease. Cortex (2009) 0.88
Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol (2003) 0.87
Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers. Breast Cancer Res Treat (2010) 0.87
Abnormal parietal function in conversion paresis. PLoS One (2011) 0.87
The syndrome of headache with neurologic deficits and cerebrospinal fluid lymphocytosis mimicking acute ischemic stroke. J Stroke Cerebrovasc Dis (2008) 0.87
1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res (2007) 0.86
TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol Dis (2003) 0.86
Myocardial beta-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388. Eur J Nucl Med Mol Imaging (2004) 0.86
Handedness and dominant side of symptoms in Parkinson's disease. Parkinsonism Relat Disord (2010) 0.85
MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol (2009) 0.85
Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci (2007) 0.84
The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. J Nucl Med (2005) 0.84
Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol (2003) 0.84
Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. Transl Oncol (2011) 0.84
Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. J Psychopharmacol (2009) 0.84